Status:
COMPLETED
Effect of Remifentanil on Electroencephalographic BAR Index During Propofol Anaesthesia
Lead Sponsor:
Melbourne Health
Collaborating Sponsors:
Biopharmica Limited
Conditions:
Depth of Anaesthesia
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
Current cortical EEG based depth of anaesthesia monitors do not accurately reflect the effect of opioid drugs. We have developed a new theoretically-based method of analysing the EEG. Our hypothesis i...
Detailed Description
Patients aged 18-60 years presenting for elective surgery under general anaesthesia will be recruited. They will be randomised to receive remifentanil effect-site target 0, 2 or 4 ng/ml. Then anaesthe...
Eligibility Criteria
Inclusion
- Male and female patients, aged 18-60 years, of ASA physical status 1-3, presenting for elective surgery under general anaesthesia
Exclusion
- Inadequate English comprehension due to a language barrier, cognitive deficit or intellectual disability
- Epilepsy or other EEG abnormality
- Prescription or illicit drugs known to affect the EEG
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00455026
Start Date
March 1 2006
End Date
October 1 2007
Last Update
May 30 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Swinburne University
Hawthorn, Victoria, Australia, 3123
2
Royal Melbourne Hospital
Parkville, Victoria, Australia, 3050